DK1102579T3 - Medicinske aerosolformuleringer - Google Patents

Medicinske aerosolformuleringer

Info

Publication number
DK1102579T3
DK1102579T3 DK99932599T DK99932599T DK1102579T3 DK 1102579 T3 DK1102579 T3 DK 1102579T3 DK 99932599 T DK99932599 T DK 99932599T DK 99932599 T DK99932599 T DK 99932599T DK 1102579 T3 DK1102579 T3 DK 1102579T3
Authority
DK
Denmark
Prior art keywords
active compounds
aerosol formulations
medical aerosol
inefficacious
nedocromil
Prior art date
Application number
DK99932599T
Other languages
English (en)
Inventor
Manfred Keller
Kurt Herzog
Rudi Mueller-Walz
Holger Kraus
Original Assignee
Jago Res Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jago Res Ag filed Critical Jago Res Ag
Application granted granted Critical
Publication of DK1102579T3 publication Critical patent/DK1102579T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK99932599T 1998-08-04 1999-08-02 Medicinske aerosolformuleringer DK1102579T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH163398 1998-08-04
PCT/CH1999/000360 WO2000007567A1 (de) 1998-08-04 1999-08-02 Medizinische aerosolformulierungen

Publications (1)

Publication Number Publication Date
DK1102579T3 true DK1102579T3 (da) 2003-07-14

Family

ID=4215022

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99932599T DK1102579T3 (da) 1998-08-04 1999-08-02 Medicinske aerosolformuleringer

Country Status (19)

Country Link
US (1) US6475467B1 (da)
EP (1) EP1102579B1 (da)
JP (1) JP4672143B2 (da)
CN (1) CN1150890C (da)
AT (1) ATE234604T1 (da)
AU (1) AU749697B2 (da)
BE (1) BE2013C027I2 (da)
CA (1) CA2338680C (da)
CY (1) CY2012033I2 (da)
DE (1) DE59904648D1 (da)
DK (1) DK1102579T3 (da)
ES (1) ES2193726T3 (da)
FR (1) FR13C0057I2 (da)
LU (1) LU92254I2 (da)
NO (2) NO328096B1 (da)
NZ (1) NZ509489A (da)
PT (1) PT1102579E (da)
WO (1) WO2000007567A1 (da)
ZA (1) ZA200100569B (da)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
PE20010720A1 (es) * 1999-12-11 2001-07-26 Glaxo Group Ltd Distribuidor de medicamento
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
DE50103666D1 (de) * 2000-10-12 2004-10-21 Boehringer Ingelheim Pharma Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
AU2174102A (en) * 2000-10-31 2002-05-15 Boehringer Ingelheim Pharma Inhalative solution formulation containing a tiotropium salt
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
ATE375142T1 (de) * 2001-03-30 2007-10-15 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
IL163843A0 (en) * 2002-03-01 2005-12-18 Chiesi Farma Spa Formoterol superfine formulation
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
US7244415B2 (en) * 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
JP5160018B2 (ja) * 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 非晶質医薬組成物を用いる経皮送達速度調節
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
KR101166955B1 (ko) * 2002-12-10 2012-07-19 선오비온 파마슈티컬스 인코포레이티드 레발부테롤 염
PT1572217E (pt) * 2002-12-12 2008-11-28 Nycomed Gmbh Medicamento combinado de r,r-formoterol e ciclesonida
US20050058606A1 (en) * 2002-12-16 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing HFC solution formulations
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
CN1292748C (zh) * 2003-03-05 2007-01-03 南昌弘益科技有限公司 噻托溴铵吸入粉雾剂及其制备工艺
ME00420B (me) * 2003-03-20 2011-12-20 Boehringer Ingelheim Pharmaceuticals Inc Formulacija, za inhalator u kojem se odmjerava doza, u kojoj se kao propelenti koriste hidro-fluoro-alkani
US20060293293A1 (en) * 2003-05-22 2006-12-28 Altana Pharma Ag Salmeterol and ciclesonide combination
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
EP1635845A1 (en) 2003-06-13 2006-03-22 ALTANA Pharma AG Formoterol and ciclesonide combination
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
AU2003254429A1 (en) * 2003-08-06 2005-02-25 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
CA2576410A1 (en) * 2003-09-18 2006-03-31 Norton Healthcare Ltd. Particles
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
DK1718336T3 (da) * 2004-02-06 2008-10-20 Meda Pharma Gmbh & Co Kg Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
AU2005210085B2 (en) 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
PL1713471T3 (pl) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
EP1720577A2 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
AU2005235384B2 (en) * 2004-04-20 2010-09-09 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
PL2708225T3 (pl) * 2004-04-23 2019-07-31 Cydex Pharmaceuticals, Inc. Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
AU2013201437B2 (en) * 2004-04-23 2015-09-03 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ITRM20040268A1 (it) * 2004-05-31 2004-08-31 Italchimici S P A Formulazione farmaceutica di una soluzione stabile di formoterolo per via inalatoria e suo precedimento di preparazione.
BRPI0512878A (pt) * 2004-07-02 2008-04-15 Boehringer Ingelheim Int formulações de suspensão de aerossol, com tg 227 ea ou tg 134 a como agente propulsor
EP1835812B1 (de) 2004-12-27 2011-08-17 Beiersdorf AG Glycopyrrolat in kosmetischen zubereitungen
JP3955868B2 (ja) * 2004-12-27 2007-08-08 株式会社キングジム 書類等の綴じ具
DE102005029390A1 (de) * 2005-06-23 2007-01-04 Beiersdorf Ag Wirkstoffkombinationen aus Glycopyrroniumbromid und Polyolen
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
EP1879571A1 (de) * 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
JP5227790B2 (ja) 2005-05-02 2013-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規結晶性臭化チオトロピウム
KR20130114229A (ko) * 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2007071313A2 (en) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
CN101568339A (zh) * 2006-12-07 2009-10-28 伊莱利利公司 普拉格雷的制品
DE102007002121B4 (de) * 2007-01-10 2008-12-11 Dräger, Karl-Heinz Verwendung eines Flüssiggasgemisches als nichtbrennbares Treibgas zum Feinstverteilen eines Reiz- oder Kampfstoffes
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
AU2010253770B9 (en) * 2009-05-29 2015-02-12 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TR200907237A2 (tr) 2009-09-23 2011-04-21 B�Lg�� Mahmut Tiotropyum kuru toz kombinasyonu
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
TR200907914A2 (tr) * 2009-10-20 2011-05-23 B�Lg�� Mahmut Kortlkosteroid içeren kuru toz formunda farmasötik bileşim.
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
PE20160853A1 (es) * 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
MX340264B (es) 2009-12-23 2016-07-04 Chiesi Farm Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR200909792A2 (tr) 2009-12-25 2011-07-21 B�Lg�� Mahmut Tiotropyum, kortikosteroid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
TR200909790A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, formoterol ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
TR200909789A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Tiotropyum, budesonid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
TR200909793A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Tiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
TR200909791A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Salmeterol ve flutikazon içeren farmasötik bileşim@
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
US20140113877A1 (en) 2011-06-15 2014-04-24 Takeda Gmbh Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds
EP2721030B1 (en) 2011-06-17 2015-12-16 Takeda GmbH Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
PE20151054A1 (es) 2012-12-17 2015-08-07 Parion Sciences Inc Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
WO2014113638A1 (en) * 2013-01-17 2014-07-24 Aer Devices, Inc. Multi-use albuterol maintenance therapy formulations and devices therefor
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
BR112016014583B1 (pt) 2013-12-30 2022-12-20 Chiesi Farmaceutici S.P.A Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição
CA2938994A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Inhalable formulations of sodium cromolyn with improved bioavailability
CN106535889A (zh) * 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3701940B1 (en) 2015-12-04 2025-11-12 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
EP3515425B1 (en) 2016-09-19 2021-06-09 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising salmeterol
US11260052B2 (en) 2016-09-19 2022-03-01 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN114515284A (zh) 2016-09-19 2022-05-20 墨西哥氟石股份公司 药物组合物
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
EA201990605A1 (ru) * 2016-10-14 2019-10-31 Распыляемые композиции тиотропия и формотерола
UA122811C2 (uk) * 2018-08-10 2021-01-06 Наталія Миколаївна Тихонівська Фармацевтична композиція
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
US12616654B2 (en) 2019-12-02 2026-05-05 Chiesi Farmaceutici S.P.A. Stainless steel can for pressurised metered dose inhalers
WO2021195328A1 (en) * 2020-03-25 2021-09-30 Insmed Incorporated Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof
US20250312274A1 (en) * 2022-05-27 2025-10-09 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227781A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227783A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (da) 1956-03-21 1900-01-01
BE556587A (da) 1957-01-31 1957-04-11
US4405598A (en) 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
FI770215A7 (da) * 1976-01-30 1977-07-31 Fisons Ltd
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
CA1075854A (en) 1976-08-16 1980-04-22 Charles W. Simons Aerosol propellants for personal products
FR2390951A1 (fr) 1977-05-17 1978-12-15 Oreal Nouvelles compositions cosmetiques sous forme de laques aerosols pour fixer la chevelure
CY1333A (en) * 1980-04-30 1986-10-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
JPS61158919A (ja) 1984-12-28 1986-07-18 Taisho Pharmaceut Co Ltd 水虫治療剤
GB8820398D0 (en) * 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
IE62780B1 (en) * 1988-09-10 1995-02-22 Fisons Plc Inhalation devices with a reduced risk of blockage
DE3839258A1 (de) * 1988-11-21 1990-05-23 Norbert Sass Verfahren zur herstellung eines suspensions-aerosols
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
IE912220A1 (en) * 1990-06-29 1992-01-01 Fisons Plc Pressurised Aerosol Compositions
HU205249B (en) * 1990-11-09 1992-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing suspensive aerosole composition
US5753208A (en) * 1990-11-09 1998-05-19 Egis Gyogyszergyar Antiasthmatic aerosol preparation of sodium cromoglycate
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DK0617610T3 (da) * 1991-12-18 1997-10-06 Minnesota Mining & Mfg Suspensionsaerosolformuleringer.
EP0550031B1 (de) 1991-12-31 1996-05-08 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
SE523661C2 (sv) 1992-02-05 2004-05-04 American Pacific Corp Gas-vätskeblandning avsedd för användning som brandsläckningsmedel
US5301664A (en) 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9214765D0 (en) 1992-07-11 1992-08-26 Smithkline Beecham Plc Pressurised aerosol formulation
WO1994003056A1 (en) 1992-07-31 1994-02-17 Ian Alexander Edwin Maccormick Aerosol insecticide composition
WO1996019198A1 (en) 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
SI0820279T1 (en) * 1995-04-14 2002-12-31 Smithkline Beecham Corporation Metered dose inhaler for albuterol
DE19616573C2 (de) * 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
FR2764899B1 (fr) 1997-06-19 2001-04-06 Boehringer Ingelheim Alimentai Nouveau melange propulseur et les preparations alimentaires en aerosol le contenant

Also Published As

Publication number Publication date
NO328096B1 (no) 2009-12-07
CY2012033I1 (el) 2015-08-05
NZ509489A (en) 2002-10-25
ATE234604T1 (de) 2003-04-15
US6475467B1 (en) 2002-11-05
EP1102579B1 (de) 2003-03-19
DE59904648D1 (de) 2003-04-24
AU4893999A (en) 2000-02-28
CN1315852A (zh) 2001-10-03
CA2338680C (en) 2008-10-14
JP2002522374A (ja) 2002-07-23
NO20010531L (no) 2001-01-31
ZA200100569B (en) 2001-09-26
WO2000007567A1 (de) 2000-02-17
CY2012033I2 (el) 2015-08-05
NO20010531D0 (no) 2001-01-31
PT1102579E (pt) 2003-07-31
AU749697B2 (en) 2002-07-04
CA2338680A1 (en) 2000-02-17
JP4672143B2 (ja) 2011-04-20
ES2193726T3 (es) 2003-11-01
FR13C0057I2 (fr) 2020-04-03
BE2013C027I2 (da) 2018-12-04
FR13C0057I1 (da) 2013-11-15
EP1102579A1 (de) 2001-05-30
NO2012019I1 (no) 2012-12-27
NO2012019I2 (no) 2014-06-02
LU92254I2 (fr) 2013-09-17
CN1150890C (zh) 2004-05-26

Similar Documents

Publication Publication Date Title
NO20010531D0 (no) Medisinske aerosolformuleringer
BR0014320A (pt) Composições de substâncias terapêuticas solúveis em tocol
BRPI0113331B8 (pt) derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
PT1087750E (pt) Formulacoes farmaceuticas para aerossois com duas ou mais substancias activas
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
DK1372608T3 (da) Medicinske aerosolformuleringer
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
EP1004315A4 (en) ANTI-IL-6 RECEPTOR ANTIBODY MEDICINES FOR THE PREVENTION AND / OR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
PT1077703E (pt) Formas de medicamentos orais com libertacao reproduzivel da substancia activa gatifloxacina ou de seus sais ou hidratos farmaceuticamente aceitaveis
BR9913135A (pt) Formulação oral
CA2352915A1 (en) Pharmaceutical compositions containing mupirocin
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
SE0102440D0 (sv) New compound
WO2002024697A1 (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
BR0317383A (pt) Metabólitos agonista de vasopressina biologicamente ativos
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
ATE342734T1 (de) Adenosin a1 antagonisten gegen männliche sterilität
NO20031650D0 (no) Nye legemidler for leversykdommer
BR0115206A (pt) Composições hidroliticamente instáveis
TR200102279T2 (tr) Metamizol içeren farmasötik efervesan (köpürücü) formülasyonu.
AR033862A1 (es) Formulacion de medicamento que contiene un agente agonista muscarinico
DE60017450D1 (de) Pharmazeutische formulierungen enthaltend salmeterol